The global amyotrophic lateral sclerosis (ALS) market is expected to grow substantially from 2025 through 2034, driven by an increasing prevalence of the disease and a robust pipeline of investigational drugs and advanced therapeutic candidates, according to a market outlook report by DelveInsight. The analysis covers current treatment practices, emerging drug pipelines, and forecasted market size across major regions including the United States, EU4 countries, the United Kingdom, and Japan.
Currently, the ALS market includes established therapies such as Riluzole, Edaravone, Radicava (including oral formulations), and QALSODY (tofersen), which address symptom management and, in some cases, specific genetic subtypes of ALS. The report notes that Radicava’s broader regulatory approvals have enhanced patient compliance and strengthened its market position.
Looking ahead, a range of novel therapies is progressing through clinical development, with several poised for regulatory submission and potential launch. These include Masitinib (AB Science), PrimeC (NeuroSense Therapeutics), RNS60 (Revalesio), Ibudilast (MediciNova), NurOwn (Brainstorm-Cell Therapeutics’ MSC-NTF cells), NP001 (Neuvivo), CNM-Au8 (Clene Nanomedicine), and CBT101 (CERES Brain Therapeutics), among others. Some investigational products target inflammation, immune modulation, and neuroprotection, while others are tailored to genetic subtypes of ALS.
The report also highlights that novel entrants such as NDC-011—developed using an AI-based drug discovery platform—have received Orphan Drug Designation and begun early clinical testing. Continued clinical trial activity is expected to expand treatment choices and stimulate market growth as these candidates advance.
In summary, rising ALS diagnosis rates and the emergence of innovative therapeutic approaches are key factors shaping market dynamics. As new drugs move toward approval and commercialization in the coming decade, the ALS market outlook points to meaningful expansion and evolving standards of care for patients living with this progressive neurodegenerative disease.
